Everett Collection / Shutterstock.com
At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP.
During World War II, as soldiers struggled to cope with injuries sustained in battle, a man called Edwin Cohn created a solution to help them recover.
The scientist invented the first practical method of what is known as blood plasma fractionation, where the conditions of pooled plasma (for example, temperature or acidity) are changed so that proteins that are normally dissolved become insoluble, aiding a speedy recovery.
At the time, the method, known as the Cohn process, was hailed as revolutionary. But fast-forward 70 years and a US company thinks it has found a new solution that will be a game-changer, and has patented it.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
PlasmaTech; pharmaceuticals; trade secrets